Karyopharm Therapeutics Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Good morning. My name is Arlinda Lee, and I'm a Senior Biotech Analyst at Canaccord Genuity. It's my pleasure to introduce the members of the management team at Karyopharm Therapeutics. With us today are Paul Richard -- sorry. I do this all the time, I'm sorry -- Richard Paulson, the President and CEO; Patricia Judson, the SVP of Medical Strategy; and Mike Mason, the Chief Financial Officer. Team, thanks for joining us today.
Thank you, Arlinda. It's great to see you. And thanks to Canaccord for hosting us at the event today. Good morning, everyone, and thank you for being here as well. Maybe I'll just share a few comments and a few slides and then we can go into the Q&A. So before we begin, please see our Safe Harbor disclaimer. Various remarks we'll make today do constitute forward-looking statements, and actual results may differ materially from those indicated by these statements.
So at Karyopharm, we are leveraging the inhibition
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |